Antagonism of fentanyl-induced respiratory depression with nalmefene.
We determined the ability of a new opioid antagonist, naimefene, to prevent fentanyl-induced respiratory depression in 8 healthy male volunteers. Ventilation and pulmonary function were measured with the respiratory inductive plethysmograph (RIP), which is non-invasive and requires no connection to the airway. Each volunteer was tested two times on different days. During the first session, each volunteer was monitored for one hour of baseline measurement followed by 4 hourly injections of fentanyl (1 microgram/kg) administered in an open-label manner. In the second session, the subjects were monitored for one hour after 1 mg of intravenous nalmefene was administered. Intravenous fentanyl or identical placebo were then given in a double-blind manner as in the first session. Progressive and profound respiratory depression occurred with fentanyl administration alone. In the absence of nalmefene, fentanyl converted normal breathing pattern to an irregular breathing pattern. When the subjects were treated with nalmefene prior to fentanyl administration, all of these changes were almost completely prevented. Pulmonary variables which reflected this difference between the fentanyl-alone group and the nalmefene-pretreated groups included frequency (p less than 0.001), tidal volume (p less than 0.001), percent rib cage contribution to tidal volume (p less than 0.001) and expiratory time (p less than 0.001). This study showed that nalmefene is an effective long-acting opioid antagonist, and that RIP accurately measures changes in respiration caused by opioid administration.
Moore
L R
LR
University of Miami, Department of Anesthesiology.
Bikhazi
G B
GB
Tuttle
R R
RR
Weidler
D J
DJ
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003864:Depression, Chemical; D004311:Double-Blind Method; D005283:Fentanyl / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D010991:Plethysmography; D012119:Respiration / Q000187:drug effects*; D012129:Respiratory Function Tests
D009271:Naltrexone; C038981:nalmefene; D005283:Fentanyl